Market revenue in 2023 | USD 229.5 million |
Market revenue in 2030 | USD 206.9 million |
Growth rate | -1.5% (CAGR from 2023 to 2030) |
Largest segment | Opioids |
Fastest growing segment | NSAIDs and Others |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDs and Others |
Key market players worldwide | Amgen Inc, Merck & Co Inc, Johnson & Johnson, Heron Therapeutics Inc, Novartis AG ADR, GSK PLC, Roche Holding AG ADR, Helsinn Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer supportive care drugs market will help companies and investors design strategic landscapes.
Opioids was the largest segment with a revenue share of 26.19% in 2023. Horizon Databook has segmented the Mexico cancer supportive care drugs market based on g-csfs (granulocyte-colony stimulating factors), esas (erythropoiesis stimulating agents), antiemetics, bisphosphonates, opioids, nsaids and others covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is anticipated to decline during the forecast period. High cancer prevalence and increased demand for chemotherapy associated cancer care drugs in the region are expected to boost the market. However, launch of biosimilars is expected to impede market growth. As per a 2020 report published in US National Library of Medicine, cancer is the third most common cause of mortality in Mexico, with breast and prostate cancers being the most common types in women & men, respectively.
Moreover, the prevalence of cancer has been growing over the past 20 years in the country, mainly due to lifestyle changes and physical inactivity. Increasing geriatric population is expected to triple by 2050 from 2015, which can further increase the prevalence of cancer, as per an article published in Oxford Academic. As per a 2018 article published in NCBI, access to innovative cancer medicines has increased over the years in Mexico.
However, compared to the U.S. and Canada, novel personalized drugs have not yet penetrated in this region, and most of them are not covered under insurance & reimbursement schemes. Thus, chemotherapy is among the most common treatments in the region, which creates demand for chemotherapy-associated cancer supportive care drugs.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico cancer supportive care drugs market , including forecasts for subscribers. This country databook contains high-level insights into Mexico cancer supportive care drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account